Page last updated: 2024-12-09

2-(2,4-dichlorophenyl)-3,5-dihydro-1H-pyrazolo[3,4-d]triazol-6-amine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're describing a chemical compound with a rather complex name. Let's break down its importance:

**2-(2,4-dichlorophenyl)-3,5-dihydro-1H-pyrazolo[3,4-d]triazol-6-amine**

* **Structure:** This compound belongs to a family of heterocyclic molecules containing nitrogen and a complex ring system. The pyrazolo[3,4-d]triazol part indicates its core structure, a fused ring system with a pyrazole and a triazole unit.
* **Substituents:** The name tells us it has a 2,4-dichlorophenyl group attached at the 2nd position, and an amino group (-NH2) at the 6th position.

**Importance for Research:**

While the exact compound name might not be readily found in common databases, its structural features point towards potential applications in several research areas:

* **Pharmacology:**
* **Potential Drug Candidate:** Heterocyclic compounds like this one are known to possess a wide range of pharmacological activities. The specific arrangement of the pyrazole and triazole rings, along with the substituted groups, could influence interactions with biological targets.
* **Anti-Cancer Agent:** Pyrazole and triazole derivatives have been investigated for their potential as anti-cancer drugs. The dichlorophenyl group might contribute to its binding affinity for specific cellular targets.
* **Anti-Inflammatory Agent:** Compounds with similar structures have been reported to have anti-inflammatory properties.

* **Materials Science:**
* **Organic Electronics:** Pyrazolo-triazole compounds have shown promise in organic electronics, including organic light-emitting diodes (OLEDs) and solar cells. The 2,4-dichlorophenyl group might influence the compound's optoelectronic properties.

**Finding More Information:**

To learn more about the specific compound you mentioned, you'll need to conduct a literature search using its full name or specific structural features. Databases like PubChem, SciFinder, and Reaxys can help you locate research papers and patents related to this compound or similar structures.

**Note:** It's important to understand that without further context or research, the specific applications and importance of this compound are unknown. The information provided here is based on general knowledge of heterocyclic compounds and their potential applications.

Cross-References

ID SourceID
PubMed CID830036
CHEMBL ID1585221
CHEBI ID107819

Synonyms (9)

Synonym
2-(2,4-dichlorophenyl)-3,5-dihydro-1h-pyrazolo[3,4-d]triazol-6-amine
AF-407/13078030
MLS000702443
2-(2,4-dichlorophenyl)-1,2,4,5-tetrahydropyrazolo[3,4-d][1,2,3]triazol-6-ylamine
smr000225380
CHEBI:107819
HMS2557B23
CHEMBL1585221
Q27186155
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency19.95260.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency11.99550.007215.758889.3584AID588342
ATAD5 protein, partialHomo sapiens (human)Potency18.12580.004110.890331.5287AID504466; AID504467
Microtubule-associated protein tauHomo sapiens (human)Potency5.74570.180013.557439.8107AID1460; AID1468
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency25.11890.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency25.11890.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency50.11870.036619.637650.1187AID2100
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency5.62340.01262.451825.0177AID485313
DNA polymerase betaHomo sapiens (human)Potency89.12510.022421.010289.1251AID485314
gemininHomo sapiens (human)Potency11.08240.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency15.84890.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency22.38720.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]